IDO1 and neoplasm: To date many cancer regimens were tested, all of them showed limited clinical efficacy, because recruiting T cells against tumor isn’t enough, it becomes functionally inactive when exposure to tumor microenvironment, which was ascribed to overexpression of IDO and regulatory mediators2,5,30.